An Open-label, Single-arm, Post- Authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Xyntha (Moroctocog-alfa (Af-cc), Recombinant Fviii) In Subjects With Hemophilia A In Usual Care Settings In China
Phase of Trial: Phase IV
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Moroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 07 Sep 2016 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Status changed from recruiting to active, no longer recruiting.